Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*

-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 -- -- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI